Global Peptide CDMO 2.0 Market Size is predicted to grow at a 12.9% CAGR during the forecast period for 2025-2034.
The next generation of contract development and manufacturing organizations (CDMOs) specializing in peptide-based therapies is known as Peptide CDMO 2.0. It goes beyond conventional services by combining cutting-edge technologies, creative procedures, and tactical partnerships to speed up drug development and production. By optimizing peptide synthesis, purification, and production through automation, machine learning, and artificial intelligence (AI), these companies’ lower costs and increase efficiency while providing real-time monitoring, predictive analytics, and improved quality control.
The modern drug development industry has identified linear peptides as a significant area of focus due to their growing use as therapeutic agents for the treatment of complex diseases, including cancer, diabetes, cardiovascular disorders, and infectious diseases. Pharmaceutical companies are searching for safer, more efficient therapies, and are particularly attracted to them for their high selectivity, low toxicity, and ability to target specific biological pathways. This trend has been further accelerated by the evolution of Peptide CDMO 2.0 (Contract Development and Manufacturing Organization), which provides scalable, flexible, and rapid production capabilities.
The primary market driver is the integration of AI-driven process optimization, machine learning algorithms, and continuous manufacturing technologies. These tools substantially reduce production costs, improve process reproducibility, and enhance yield, thereby rendering linear peptide manufacturing more economically viable. The favorable conditions for innovation have been established by technological advancements in peptide synthesis automation, broadened R&D investments by biotech and pharmaceutical companies, and encouraging regulatory frameworks for peptide therapeutics. The importance of peptide CDMOs in the value chain has also expanded with the global push toward biopharmaceutical outsourcing, driven by the need for cost efficiency and specialized expertise. Peptide CDMO 2.0 has become a cornerstone of the swiftly evolving peptide therapeutics market, nurturing continuous innovation and accelerating the path from drug discovery to commercialization, which is driven by these factors and technological enablers.
Some of the Major Key Players in the Peptide CDMO 2.0 Market are
· Lonza Group AG
· CordenPharma
· Bachem Holding AG
· AmbioPharm
· PolyPeptide Group
· Evonik Health Care
· WuXi AppTec / WuXi TIDES
· Thermo Fisher Scientific (Patheon)
· Olon S.p.A.
· NOF Corporation
· Curapath
· eTheRNA Manufacturing
· Helix Biotech
· Phosphorex
· Creative Peptides
· Peptron Inc.
· Pepscan
· CSBio
· Neuland Laboratories
· Asymchem
· Sai Life Sciences
· AmbioPharm Shanghai
· Hybio Pharmaceutical
The Peptide CDMO 2.0 Market is segmented into product type/modality, scale of operation, business model, technology platform, therapeutic area, and end user. Based on the product type/ modality, the market is segmented into linear peptides, cyclic peptides, stapled peptides, peptide–drug conjugates (PDCS), peptide–oligonucleotide conjugates, GLP-1 and related long-acting analogues, and oral peptide formulations. Based on the scale of operation, the market is divided into preclinical, clinical (Phase I–III), and commercial. Based on the Business Model, the market is divided into tech-enabled CDMS, niche-focused CDMS, end-to-end integrated CDMS, and sustainability-driven CDMS. Based on the technology platform, the market is divided into solid phase peptide synthesis (SPPS), liquid phase peptide synthesis (LPPS), hybrid SPPS–LPPS, enzymatic/biocatalytic synthesis, AI-assisted synthesis optimization. Based on the therapeutic area, the market is divided into oncology, metabolic disorders, infectious diseases, rare & genetic disorders, cardiovascular, and neurology. Based on the End User, the market is divided into large pharmaceutical companies, emerging biotechs, and academic & research institutions.
The cyclic peptides segment is projected to experience the highest growth rate during the forecast period, primarily due to superior structural and pharmacological properties relative to linear peptides. Cyclic peptides demonstrate high efficacy in treating complex diseases, including cancer, infectious diseases, and autoimmune disorders, because of enhanced membrane permeability, increased binding affinity to biological targets, and improved stability against enzymatic degradation. These properties increase therapeutic potential, extend bioavailability, and lengthen half-life, positioning cyclic peptides as strong candidates for next-generation peptide-based pharmaceuticals. The rise of precision medicine and biologics has further increased demand for cyclic peptides, as their tunable conformations and structural diversity enable highly selective interactions with molecular targets. Consequently, pharmaceutical and biotechnology companies increasingly depend on peptide contract development and manufacturing organization (CDMO) 2.0 providers, who possess advanced manufacturing capabilities and specialized expertise for developing these complex molecules.
SPPS is critical for synthesizing both linear peptides (easier to produce) and cyclic peptides (requiring additional cyclization steps). Peptide CDMO 2.0 providers use SPPS to produce complex peptides with modifications like disulfide bonds, stapling, or conjugation, meeting the demand for advanced therapeutics. The increasing pipeline of peptide drugs, particularly for chronic diseases, drives demand for SPPS-based manufacturing. Peptide CDMO 2.0 providers meet this demand by offering high-throughput SPPS capabilities, ensuring rapid delivery of clinical and commercial supplies. Peptide CDMO 2.0 provides end-to-end services, from SPPS-based peptide synthesis to purification, analytical testing, and GMP-compliant manufacturing. This integrated approach streamlines development and reduces tech transfer challenges, accelerating time-to-market for peptide drugs.
North America has state-of-the-art facilities, advanced manufacturing technologies, and a skilled workforce, enabling Peptide CDMO 2.0 providers to deliver high-quality, complex peptides with precision. The region’s advanced analytical capabilities and quality control systems ensure compliance with stringent regulatory standards, making it a preferred hub for peptide production. Peptide CDMO 2.0 providers in North America support this demand by offering scalable, high-quality manufacturing and development services, leveraging advanced SPPS and digital tools. The growing trend toward personalized medicine has driven demand for customized peptide therapeutics in North America. Peptide CDMO 2.0 providers are adapting by offering flexible manufacturing platforms for small-batch production of tailored peptides, supported by advanced analytics and digital twins for process optimization.
· In January 2024, WuXi AppTec launched two new peptide manufacturing plants, one in Changzhou and another at their new Taixing API site in China, tripling their overall peptide synthesis capacity and increasing total Solid-Phase Peptide Synthesis (SPPS) reactor volume to 32,000 liters. These advanced facilities use digital operations and automated solvent delivery systems to improve production efficiency, consistency, and scalability.
· In May 2023, PolyPeptide and Numaferm signed a Preferred Partner Collaboration Agreement for peptide development and production, utilizing Numaferm's biochemical production platform and sustainable peptide manufacturing expertise, as well as PolyPeptide's cGMP manufacturing capabilities, regulatory expertise, and market access. The company specializes in the development and production of peptides and proteins. The parties have committed to maintaining the confidentiality of the agreement's specifics.
|
Specifications |
|
|
Growth Rate CAGR |
CAGR of 12.9 % from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Mn and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Product Type / Modality, Scale of Operation, Business Model, Technology Platform, Therapeutic Area, End User |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; South East Asia |
|
Competitive Landscape |
Lonza Group AG, CordenPharma, Bachem Holding AG, AmbioPharm, PolyPeptide Group, Evonik Health Care, WuXi AppTec / WuXi TIDES, Thermo Fisher Scientific (Patheon), Olon S.p.A., NOF Corporation, Curapath, eTheRNA Manufacturing, Helix Biotech, Phosphorex, Creative Peptides, Peptron Inc., Pepscan, CSBio, Neuland Laboratories, Asymchem, Sai Life Sciences, AmbioPharm Shanghai, Hybio Pharmaceutical |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Peptide CDMO 2.0 Market Snapshot
Chapter 4. Global Peptide CDMO 2.0 Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2034
4.8. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.9. Use/impact of AI on Peptide CDMO 2.0 Market Industry Trends
4.10. Global Peptide CDMO 2.0 Market Penetration & Growth Prospect Mapping (US$ Mn), 2021-2034
Chapter 5. Peptide CDMO 2.0 Market Segmentation 1: By Product Scale of Operation / Modality, Estimates & Trend Analysis
5.1. Market Share By Product Scale of Operation / Modality, 2024 & 2034
5.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Product:
5.2.1. Linear peptides
5.2.2. Cyclic peptides
5.2.3. Stapled peptides
5.2.4. Peptide–drug conjugates (PDCs)
5.2.5. Peptide–oligonucleotide conjugates
5.2.6. GLP-1 and related long-acting analogues
5.2.7. Oral peptide formulations
Chapter 6. Peptide CDMO 2.0 Market Segmentation 2: By Scale of Operation, Estimates & Trend Analysis
6.1. Market Share by Scale of Operation, 2024 & 2034
6.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Scale of Operation:
6.2.1. Preclinical
6.2.2. Clinical (Phase I–III)
6.2.3. Commercial
Chapter 7. Peptide CDMO 2.0 Market Segmentation 3: By Business Model, Estimates & Trend Analysis
7.1. Market Share by Business Model, 2024 & 2034
7.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Business Model
7.2.1. Tech-Enabled CDMOs (automation, AI, data integration)
7.2.2. Niche-Focused CDMOs (rare diseases, complex peptides)
7.2.3. End-to-End Integrated CDMOs
7.2.4. Sustainability-Driven CDMOs
Chapter 8. Peptide CDMO 2.0 Market Segmentation 4: By Technology Platform, Estimates & Trend Analysis
8.1. Market Share by Technology Platform, 2024 & 2034
8.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Technology Platform:
8.2.1. Solid Phase Peptide Synthesis (SPPS)
8.2.2. Liquid Phase Peptide Synthesis (LPPS)
8.2.3. Hybrid SPPS–LPPS
8.2.4. Enzymatic/biocatalytic synthesis
8.2.5. AI-assisted synthesis optimization
Chapter 9. Peptide CDMO 2.0 Market Segmentation 5: By End-user, Estimates & Trend Analysis
9.1. Market Share by End-user, 2024 & 2034
9.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following End-user:
9.2.1. Large pharmaceutical companies
9.2.2. Emerging biotechs
9.2.3. Academic & research institutions
Chapter 10. Peptide CDMO 2.0 Market Segmentation 6: By Therapeutic Area, Estimates & Trend Analysis
10.1. Market Share by By Therapeutic Area, 2024 & 2034
10.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Therapeutic Area:
10.2.1. Oncology
10.2.2. Metabolic disorders (incl. obesity/diabetes)
10.2.3. Infectious diseases
10.2.4. Rare & genetic disorders
10.2.5. Cardiovascular
10.2.6. Neurology
Chapter 11. Peptide CDMO 2.0 Market Segmentation 7: Regional Estimates & Trend Analysis
11.1. Global Peptide CDMO 2.0 Market, Regional Snapshot 2024 & 2034
11.2. North America
11.2.1. North America Peptide CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
11.2.1.1. US
11.2.1.2. Canada
11.2.2. North America Peptide CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts By Product Scale of Operation / Modality, 2021-2034
11.2.3. North America Peptide CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Scale of Operation, 2021-2034
11.2.4. North America Peptide CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Business Model, 2021-2034
11.2.5. North America Peptide CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Technology Platform, 2021-2034
11.2.6. North America Peptide CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by End-user, 2021-2034
11.2.7. North America Peptide CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2021-2034
11.3. Europe
11.3.1. Europe Peptide CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
11.3.1.1. Germany
11.3.1.2. U.K.
11.3.1.3. France
11.3.1.4. Italy
11.3.1.5. Spain
11.3.1.6. Rest of Europe
11.3.2. Europe Peptide CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts By Product Scale of Operation / Modality, 2021-2034
11.3.3. Europe Peptide CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Scale of Operation, 2021-2034
11.3.4. Europe Peptide CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Business Model, 2021-2034
11.3.5. Europe Peptide CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Technology Platform, 2021-2034
11.3.6. Europe Peptide CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by End-user, 2021-2034
11.3.7. Europe Peptide CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2021-2034
11.4. Asia Pacific
11.4.1. Asia Pacific Peptide CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
11.4.1.1. India
11.4.1.2. China
11.4.1.3. Japan
11.4.1.4. Australia
11.4.1.5. South Korea
11.4.1.6. Hong Kong
11.4.1.7. Southeast Asia
11.4.1.8. Rest of Asia Pacific
11.4.2. Asia Pacific Peptide CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts By Product Scale of Operation / Modality, 2021-2034
11.4.3. Asia Pacific Peptide CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Scale of Operation, 2021-2034
11.4.4. Asia Pacific Peptide CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts Technology Platform, 2021-2034
11.4.5. Asia Pacific Peptide CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by End-User , 2021-2034
11.4.6. Asia Pacific Peptide CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2021-2034
11.5. Latin America
11.5.1. Latin America Peptide CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
11.5.1.1. Brazil
11.5.1.2. Mexico
11.5.1.3. Rest of Latin America
11.5.2. Latin America Peptide CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts By Product Scale of Operation / Modality, 2021-2034
11.5.3. Latin America Peptide CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Scale of Operation, 2021-2034
11.5.4. Latin America Peptide CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Business Model, 2021-2034
11.5.5. Latin America Peptide CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Technology Platform, 2021-2034
11.5.6. Latin America Peptide CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by End-User Therapeutic Area, 2021-2034
11.5.7. Latin America Peptide CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2021-2034
11.6. Middle East & Africa
11.6.1. Middle East & Africa Wind Turbine Rotor Blade Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
11.6.1.1. GCC Countries
11.6.1.2. Israel
11.6.1.3. South Africa
11.6.1.4. Rest of Middle East and Africa
11.6.2. Middle East & Africa Peptide CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts By Product Scale of Operation / Modality, 2021-2034
11.6.3. Middle East & Africa Peptide CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Scale of Operation, 2021-2034
11.6.4. Middle East & Africa Peptide CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Business Model, 2021-2034
11.6.5. Middle East & Africa Peptide CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Technology Platform, 2021-2034
11.6.6. Middle East & Africa Peptide CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by End-user, 2021-2034
11.6.7. Middle East & Africa Peptide CDMO 2.0 Market Revenue (US$ Million) Estimates and Forecasts by Therapeutic Area, 2021-2034
Chapter 12. Competitive Landscape
12.1. Major Mergers and Acquisitions/Strategic Alliances
12.2. Company Profiles
12.2.1. Lonza Group AG
12.2.1.1. Business Overview
12.2.1.2. Key Product/Service Overview
12.2.1.3. Financial Performance
12.2.1.4. Geographical Presence
12.2.1.5. Recent Developments with Business Strategy
12.2.2. CordenPharma
12.2.3. Bachem Holding AG
12.2.4. AmbioPharm
12.2.5. PolyPeptide Group
12.2.6. Evonik Health Care
12.2.7. WuXi AppTec / WuXi TIDES
12.2.8. Thermo Fisher Scientific (Patheon)
12.2.9. Olon S.p.A.
12.2.10. NOF Corporation
12.2.11. Curapath
12.2.12. eTheRNA Manufacturing
12.2.13. Helix Biotech
12.2.14. Phosphorex
12.2.15. Creative Peptides
12.2.16. Peptron Inc.
12.2.17. Pepscan
12.2.18. CSBio
12.2.19. Neuland Laboratories
12.2.20. Asymchem
12.2.21. Sai Life Sciences
12.2.22. AmbioPharm Shanghai
12.2.23. Hybio Pharmaceutical
Global Peptide CDMO 2.0 Market- By Product Type / Modality
· Linear peptides
· Cyclic peptides
· Stapled peptides
· Peptide–drug conjugates (PDCs)
· Peptide–oligonucleotide conjugates
· GLP-1 and related long-acting analogues
· Oral peptide formulations
Global Peptide CDMO 2.0 Market – By Scale of Operation
· Preclinical
· Clinical (Phase I–III)
· Commercial
Global Peptide CDMO 2.0 Market – By Business Model
· Tech-Enabled CDMOs (automation, AI, data integration)
· Niche-Focused CDMOs (rare diseases, complex peptides)
· End-to-End Integrated CDMOs
· Sustainability-Driven CDMOs
Global Peptide CDMO 2.0 Market- By Technology Platform
· Solid Phase Peptide Synthesis (SPPS)
· Liquid Phase Peptide Synthesis (LPPS)
· Hybrid SPPS–LPPS
· Enzymatic/biocatalytic synthesis
· AI-assisted synthesis optimization
Global Peptide CDMO 2.0 Market – By Therapeutic Area
· Oncology
· Metabolic disorders (incl. obesity/diabetes)
· Infectious diseases
· Rare & genetic disorders
· Cardiovascular
· Neurology
Global Peptide CDMO 2.0 Market – By End User
· Large pharmaceutical companies
· Emerging biotechs
· Academic & research institutions
Global Peptide CDMO 2.0 Market – By Region
North America-
· The US
· Canada
Europe-
· Germany
· The UK
· France
· Italy
· Spain
· Rest of Europe
Asia-Pacific-
· China
· Japan
· India
· South Korea
· Southeast Asia
· Rest of Asia Pacific
Latin America-
· Brazil
· Argentina
· Mexico
· Rest of Latin America
Middle East & Africa-
· GCC Countries
· South Africa
· Rest of the Middle East and Africa
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
